Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.
机构：[1]The Second Department of General Surgery, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.临床科室外二科河北医科大学第四医院[2]Ward 1 of Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.[3]Ward 2 of Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.[4]Department of Endocrinology, the First Hospital of Xingtai, Xingtai, Hebei Province, China.[5]Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.临床科室肿瘤内科河北医科大学第四医院[6]Department of Osteology, the First Hospital of Xingtai, Xingtai, Hebei Province, China.
Colorectal cancer (CRC) is the third most frequently diagnosed cancer and this study aimed to develop a conatumumab decorated, irinotecan prodrug and quercetin co-loaded delivery system for combined and targeted colorectal cancer treatment.A conatumumab (C) decorated, irinotecan prodrug (I-p) and quercetin (Q) co-encapsulated NLC (C I-p/Q NLC) was developed. In vitro and in vivo antitumor efficiency of NLC was evaluated on CRC cells and mice xenograft.The results showed that the HT-29 cells uptake of C I-p/Q NLC was over 70%. Reactive oxygen species (ROS) sensitive irinotecan prodrug formulation showed improved drug release ability in hypoxic conditions. C I-p/Q NLC showed significantly higher cytotoxicity than non-decorated NLC, single drug-loaded NLC and free drugs. In vivo studies in a CRC-bearing model corroborated the capability of nanoparticles for the inhibition of cancer, leading to a reduction of tumor growth without systemic toxicity.The conatumumab decorated, ROS sensitive prodrug contained combination nano-system is a promising platform for CRC therapy.
第一作者机构：[1]The Second Department of General Surgery, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.
共同第一作者：
通讯作者：
通讯机构：[5]Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.[6]Department of Osteology, the First Hospital of Xingtai, Xingtai, Hebei Province, China.[*1]Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, 050010, China[*2]Department of Osteology, the First Hospital of Xingtai, Xingtai, Hebei Province, 054001, China
推荐引用方式(GB/T 7714)：
Liu Youqiang,Zhang Hongxin,Cui Haijing,et al.Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.[J].DRUG DELIVERY.2022,29(1):342-350.doi:10.1080/10717544.2022.2027573.
APA：
Liu Youqiang,Zhang Hongxin,Cui Haijing,Zhang Futong,Zhao Liyan...&Meng Qingju.(2022).Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers..DRUG DELIVERY,29,(1)
MLA：
Liu Youqiang,et al."Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.".DRUG DELIVERY 29..1(2022):342-350
